Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at confirming
tumor targeting and accurately estimating radiation dose delivery to both tumor and normal …

Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT)
candidates to confirm tumor targeting and to estimate radiation doses to tumor and normal …

Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at the
confirmation of tumor targeting and the accurate estimation of radiation dose delivery to both …

The use of immuno-PET, the combination of PET with monoclonal antibodies (mAbs), is an
attractive option to improve tumor detection and mAb quantification. The long-lived positron …

Abstract Purpose Targeting the c-Met receptor with monoclonal antibodies (MAbs) is an
appealing approach for cancer diagnosis and treatment because this receptor plays a …

Purpose Immuno-PET is an emerging imaging tool for the selection of high potential
antibodies (mAbs) for imaging and therapy. The positron emitter zirconium-89 (89 Zr) has …

Immuno-PET using desferrioxamine (DFO)-conjugated zirconium-89 ([89Zr] Zr4+)-labeled
antibodies is a powerful tool used for preclinical and clinical molecular imaging. However, a …

Absorbed doses in 90Y radioimmunotherapy are usually estimated by extrapolating from
111In imaging data. PET using 86Y (β+ 33%; half-life, 14.7 h) as a surrogate radiolabel …

89Zr-immuno-PET is a promising noninvasive clinical tool that measures target engagement
of monoclonal antibodies (mAbs) to predict toxicity in normal tissues and efficacy in tumors …

Abstract Purpose All clinical 89 Zr-immuno-PET studies are currently performed with the
chelator desferrioxamine (DFO). This chelator provides hexadentate coordination to …